Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease-Reference-Cited by-同舟云学术

Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease

Published:2023-08 Issue:8 Volume:11 Page:933-942
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Hussain Aliza,Ramsey David,Lee Michelle,Mahtta Dhruv,Khan Muhammad Shahzeb,Nambi Vijay,Ballantyne Christie M.,Petersen Laura A.,Walker Adrienne D.,Kayani Waleed T.,Butler Javed,Slipczuk Leandro^ORCID,Rogers Joseph G.,Bozkurt Biykem^ORCID,Navaneethan Sankar D.,Virani Salim S.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference33 articles.

1. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study;Roth;J Am Coll Cardiol,2020

2. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

4. SGLT-2 inhibitors for patients with heart failure: what have we learned recently?;Al Rifai;Curr Atheroscler Rep,2022

5. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Heidenreich;J Am Coll Cardiol,2022

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge;JACC: Heart Failure;2024-06

2. Exploring novel lead scaffolds for SGLT2 inhibitors: Insights from machine learning and molecular dynamics simulations;International Journal of Biological Macromolecules;2024-04

3. Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021;American Heart Journal;2024-02

4. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk;Diabetes Epidemiology and Management;2024-01

5. 2023 Update in ambulatory general internal medicine;Cleveland Clinic Journal of Medicine;2024-01